Arrowhead Subsidiary, Calando Pharmaceuticals Publishes Study on
Targeted, Systemic Delivery of siRNA
PASADENA, Calif.--(BUSINESS WIRE)--Mar 20, 2007 - Arrowhead
Research Corporation (NASDAQ:ARWR) announced today that
majority-owned subsidiary
Calando Pharmaceuticals has published
results in the Proceedings of the National Academy of Sciences
(PNAS) of the first non-human primate study to use multi...
Arrowhead Subsidiary Calando Pharmaceuticals Publishes Study
Showing Anti-Cancer Effect with Lead RNAi Candidate
PASADENA, Calif.--(BUSINESS WIRE)--Apr 3, 2007 - Arrowhead Research
Corporation (NASDAQ: ARWR) announced the publication by its
majority-owned subsidiary
Calando Pharmaceuticals, Inc. of a study
demonstrating the anti-proliferative effect of the siRNA sequence
selected as the therapeutic component ...
Arrowhead Subsidiaries Insert & Calando Present Data on
Cyclosert Drug Delivery System at AACR Meeting
Novel Systems May Provide Cancer Patients With Improved Potential
to Battle Their Disease
PASADENA, Calif., April 16, 2007 /PRNewswire-FirstCall/ --
Arrowhead Research Corporation announced today that two of its
majority-owned subsidiaries, Insert Therapeutics Inc. and Calando
Pharmaceuticals Inc....
Calando Pharmaceuticals Publishes the First Non-Human Primate Study
on Targeted, Systemic Delivery of siRNA in National Academy of
Sciences Journal
...s to cause
highly targeted gene silencing.
About
calando Pharmaceuticals Inc.
calando Pharmaceuticals Inc. (www.calandopharma.com), a ma...with pharmaceutical and
biotechnology companies.
calando Technology
Calando's cyclodextrin-containing pol...
Calando Pharmaceuticals Publishes Study Showing Anti-Cancer Effect
with Lead RNAi Candidate
...f Cancer
Research (AACR). This paper describes how
calando researchers and
their collaborators determined the...Chief Executive Officer. Petrovich also noted that
calando has
filed for patent protection on several siRNA d...s to cause
highly targeted gene silencing.
About
calando Pharmaceuticals Inc.
...
Calando Pharmaceuticals Announces Preclinical Efficacy and Safety
Data of Targeted, Systemic Delivery of siRNA at AACR Annual Meeting
...," said
Jeremy Heidel, Chief Scientific Officer at
calando Pharmaceuticals.
"This formulation was well-tolera... cells has
also been accomplished in vivo.
About
calando Pharmaceuticals Inc.
calando Pharmaceuticals Inc. (
Breaking Medicine News(10 mins):Health News:Pack Right for the Holidays to Avoid the ER 2Health News:Text Messages from Santa | Santa goes GREEN by going MOBILE for The March of Dimes 2Health News:Dr. Douglas Macmillan Now Providing LUMINEERS at Research Triangle Dental 2Health News:Ennis & Ennis, P.A. Announces Nationwide Free, Confidential, Consultations For Users Of Yaz And Yasmin Birth Control Pills 2Health News:Ennis & Ennis, P.A. Announces Nationwide Free, Confidential, Consultations For Users Of Yaz And Yasmin Birth Control Pills 3Health News:Kansas City Prepares for Largest Free Health Clinic 2